Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
Jazyk angličtina Země Spojené státy americké Médium electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
32152297
PubMed Central
PMC7062899
DOI
10.1038/s41408-020-0300-y
PII: 10.1038/s41408-020-0300-y
Knihovny.cz E-zdroje
- MeSH
- doba přežití bez progrese choroby MeSH
- lidé MeSH
- mnohočetný myelom farmakoterapie mortalita MeSH
- oligopeptidy farmakologie terapeutické užití MeSH
- progrese nemoci MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- carfilzomib MeSH Prohlížeč
- oligopeptidy MeSH
The phase 3 A.R.R.O.W. study demonstrated that treatment with once-weekly carfilzomib (70 mg/m2) and dexamethasone (once-weekly Kd70 mg/m2) improved progression-free survival compared with twice-weekly carfilzomib (27 mg/m2) and dexamethasone (twice-weekly Kd27 mg/m2) in patients with relapsed and refractory multiple myeloma (RRMM; median, 11.2 versus 7.6 months; hazard ratio [HR] = 0.69; 95% confidence interval, 0.54-0.88; P = 0.0029). Once-weekly dosing also improved response rates and depth of response. We performed a subgroup analysis from A.R.R.O.W. according to age (<65, 65-74, or ≥75 years), renal function (creatinine clearance <50, ≥50-<80, or ≥80 mL/min), number of prior therapies (2 or 3), and bortezomib-refractory status (yes or no). Compared with twice-weekly Kd27 mg/m2, once-weekly Kd70 mg/m2 reduced the risk of progression or death (HR = 0.60-0.85) and increased overall response rates in nearly all the examined subgroups, consistent with reports in the overall A.R.R.O.W. population. The safety profiles of once-weekly Kd70 mg/m2 across subgroups were also generally consistent with those in the overall population. Findings from this subgroup analysis generally demonstrate a favorable benefit-risk profile of once-weekly Kd70 mg/m2, further supporting once-weekly carfilzomib dosing as an appropriate treatment option for patients with RRMM, regardless of baseline patient and disease characteristics.
Amgen Inc Thousand Oaks CA USA
Center for Myeloma New York Presbyterian Hospital Weill Cornell Medical Center New York NY USA
Hematology Department University Hospital Hotel Dieu Nantes France
Hematology Service University Hospital Salamanca Spain
John Theurer Cancer Center at Hackensack University Medical Center Hackensack NJ USA
National and Kapodistrian University of Athens Athens Greece
Zobrazit více v PubMed
Kumar SK, et al. Multiple myeloma. Nat. Rev. Dis. Primers. 2017;3:17046. doi: 10.1038/nrdp.2017.46. PubMed DOI
Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210. PubMed DOI
Cook G, Zweegman S, Mateos MV, Suzan F, Moreau P. A question of class: treatment options for patients with relapsed and/or refractory multiple myeloma. Crit. Rev. Oncol. Hematol. 2018;121:74–89. doi: 10.1016/j.critrevonc.2017.11.016. PubMed DOI
Sonneveld P, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955–2962. doi: 10.1182/blood-2016-01-631200. PubMed DOI PMC
Dingli D, et al. Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy. Mayo Clin. Proc. 2017;92:578–598. doi: 10.1016/j.mayocp.2017.01.003. PubMed DOI PMC
Kumar SK, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin. Proc. 2004;79:867–874. doi: 10.4065/79.7.867. PubMed DOI
Tandon N, et al. Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer J. 2017;7:e528. doi: 10.1038/bcj.2017.13. PubMed DOI PMC
Eleutherakis-Papaiakovou V, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk. Lymphoma. 2007;48:337–341. doi: 10.1080/10428190601126602. PubMed DOI
Willan J, et al. Multiple myeloma in the very elderly patient: challenges and solutions. Clin. Interv. Aging. 2016;11:423–435. PubMed PMC
Laubach J, et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2016;30:1005–1017. doi: 10.1038/leu.2015.356. PubMed DOI
Kim H, et al. Efficacy and safety of once-weekly bortezomib infusion in the treatment of relapsed/refractory multiple myeloma. Blood. 2011;118:5141. doi: 10.1182/blood.V118.21.5141.5141. PubMed DOI
Hainsworth JD, et al. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer. 2008;113:765–771. doi: 10.1002/cncr.23606. PubMed DOI
Moreau Philippe, Kumar Shaji, Boccia Ralph, Iida Shinsuke, Goldschmidt Hartmut, Cocks Kim, Trigg Andrew, Zahlten-Kumeli Anita, Yucel Emre, Panjabi Sumeet S., Dimopoulos Meletios. Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study) Leukemia. 2019;33(12):2934–2946. doi: 10.1038/s41375-019-0480-2. PubMed DOI
Siegel DS, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817–2825. doi: 10.1182/blood-2012-05-425934. PubMed DOI PMC
KYPROLIS®. KYPROLIS® (carfilzomib) [prescribing information] (Onyx Pharmaceuticals, Inc, South San Francisco, CA, 2018).
Dimopoulos MA, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38. doi: 10.1016/S1470-2045(15)00464-7. PubMed DOI
Stewart AK, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 2015;372:142–152. doi: 10.1056/NEJMoa1411321. PubMed DOI
Siegel DS, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J. Clin. Oncol. 2018;36:728–734. doi: 10.1200/JCO.2017.76.5032. PubMed DOI
Dimopoulos MA, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1327–1337. doi: 10.1016/S1470-2045(17)30578-8. PubMed DOI
Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br. J. Haematol. 2017;177:404–413. doi: 10.1111/bjh.14549. PubMed DOI PMC
Ludwig H, et al. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leuk. Lymphoma. 2017;58:2501–2504. doi: 10.1080/10428194.2017.1298755. PubMed DOI
Dimopoulos MA, et al. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017;7:e554. doi: 10.1038/bcj.2017.31. PubMed DOI PMC
Moreau P, et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017;31:115–122. doi: 10.1038/leu.2016.186. PubMed DOI PMC
Avet-Loiseau H, et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016;128:1174–1180. doi: 10.1182/blood-2016-03-707596. PubMed DOI PMC
Chng WJ, et al. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017;31:1368–1374. doi: 10.1038/leu.2016.390. PubMed DOI PMC
Dimopoulos MA, et al. Superior efficacy of carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in multiple myeloma (MM) patients with moderate or serious renal failure: a subgroup analysis of the phase 3 ENDEAVOR study. Blood. 2017;130:1845. doi: 10.1182/blood-2017-05-786004. PubMed DOI PMC
Moreau P, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19:953–964. doi: 10.1016/S1470-2045(18)30354-1. PubMed DOI
Durie BG, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473. doi: 10.1038/sj.leu.2404284. PubMed DOI
Rajkumar SV, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691–4695. doi: 10.1182/blood-2010-10-299487. PubMed DOI PMC
Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J. Support. Oncol. 2003;1(4 Suppl 2):18–24. PubMed
Yancik R, Ganz PA, Varricchio CG, Conley B. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J. Clin. Oncol. 2001;19:1147–1151. doi: 10.1200/JCO.2001.19.4.1147. PubMed DOI
Qian Y, et al. Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States. Cancer Med. 2017;6:1523–1530. doi: 10.1002/cam4.1075. PubMed DOI PMC
Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Med. Clin. North Am. 2005;89:649–687. doi: 10.1016/j.mcna.2004.11.007. PubMed DOI
Kurtin SE. Relapsed or relapsed/refractory multiple myeloma. J. Adv. Pract. Oncol. 2013;4(Suppl 1):5–14.
Ziogas DC, Terpos E, Kastritis E, Dimopoulos MA. An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opin. Pharmacother. 2017;18:1883–1897. doi: 10.1080/14656566.2017.1404575. PubMed DOI
Muchtar E, et al. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. Br. J. Haematol. 2016;172:89–96. doi: 10.1111/bjh.13799. PubMed DOI
Facon T, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131:301–310. doi: 10.1182/blood-2017-07-795047. PubMed DOI PMC
Pulte ED, et al. FDA approval summary: lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma. Oncologist. 2018;23:734–739. doi: 10.1634/theoncologist.2017-0440. PubMed DOI PMC
Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treat. Rev. 2015;41:827–835. doi: 10.1016/j.ctrv.2015.07.005. PubMed DOI
Palumbo A, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J. Clin. Oncol. 2014;32:587–600. doi: 10.1200/JCO.2013.48.7934. PubMed DOI PMC
National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: multiple myeloma version 2.2019. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf (2019). Accessed 15 October (2019). PubMed
Mikhael J, et al. Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline. J. Clin. Oncol. 2019;10:1228–1263. doi: 10.1200/JCO.18.02096. PubMed DOI
Dimopoulos MA, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 2016;375:1319–1331. doi: 10.1056/NEJMoa1607751. PubMed DOI
Dimopoulos MA, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018;103:2088–2096. doi: 10.3324/haematol.2018.194282. PubMed DOI PMC
Palumbo A, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 2016;375:754–766. doi: 10.1056/NEJMoa1606038. PubMed DOI
Spencer A, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018;103:2079–2087. doi: 10.3324/haematol.2018.194118. PubMed DOI PMC
Mateos Maria-Victoria, Spencer Andrew, Nooka Ajay K., Pour Ludek, Weisel Katja, Cavo Michele, Laubach Jacob P., Cook Gordon, Iida Shinsuke, Benboubker Lotfi, Usmani Saad Z., Yoon Sung-Soo, Bahlis Nizar J., Chiu Christopher, Ukropec Jon, Schecter Jordan M., Qin Xiang, O’Rourke Lisa, Dimopoulos Meletios A. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica. 2019;105(2):468–477. doi: 10.3324/haematol.2019.217448. PubMed DOI PMC
